Tag: Adcetris
Pfizer to acquire cancer drugmaker Seagen for $43bn in cash
American pharmaceutical and biotechnology company Pfizer has agreed to acquire cancer drugmaker Seagen (formerly Seattle Genetics) for $229 per share or $43 billion in cash, ... Read More
Takeda gets extended EC approval for ADCETRIS in sALCL
Takeda Pharmaceutical has secured extended approval for ADCETRIS (brentuximab vedotin) in the European Union to include the treatment of previously untreated systemic anaplastic large cell ... Read More
Seattle Genetics’ Adcetris gets FDA approval for peripheral T-cell lymphoma
Adcetris FDA approval : Seattle Genetics has secured new approval from the US Food and Drug Administration (FDA) for its monoclonal antibody Adcetris (brentuximab vedotin), ... Read More